Cell cycle-related changes in transient K(+) current density in the GH3 pituitary cell line. 2000

A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
Laboratoire de Neurophysiologie, Centre National de la Recherche Scientifique UMR 5543, Université de Bordeaux 2, 33076 Bordeaux Cedex, France.

Our aim was to determine whether the expression of K(+) currents is related to the cell cycle in the excitable GH3 pituitary cell line. K(+) currents were studied by electrophysiology, and bromodeoxyuridine (BrdU) labeling was used to compare their expression in cells thereafter identified as being in the S or non-S phase of the cell cycle. We show that the peak density of the transient outward K(+) current (I(to)) was 33% lower in cells in S phase (BrdU+) than in cells in other phases of the cell cycle (BrdU-). The voltage-dependence of I(to) was not modified. However, of the two kinetic components of I(to) inactivation, the characteristics of the fast component differed significantly between BrdU+ and BrdU- cells. Recovery from inactivation of I(to) showed biexponential and monoexponential function in BrdU- and BrdU+ cells, respectively. This suggests that the molecular basis of this current varies during the cell cycle. We further demonstrated that 4-aminopyridine, which blocks I(to), inhibited GH3 cell proliferation without altering the membrane potential. These data suggest that I(to) may play a role in GH3 cell proliferation processes.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D014316 Tritium The radioactive isotope of hydrogen also known as hydrogen-3. It contains two NEUTRONS and one PROTON in its nucleus and decays to produce low energy BETA PARTICLES. Hydrogen-3,Hydrogen 3

Related Publications

A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
August 1976, Life sciences,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
July 1997, The American journal of physiology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
July 1991, The American journal of physiology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
December 1998, Journal of cellular physiology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
March 1989, The Journal of physiology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
April 1993, Endocrinology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
January 1994, The Japanese journal of physiology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
July 1999, Neuropharmacology,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
January 1990, Brain research,
A Czarnecki, and S Vaur, and L Dufy-Barbe, and B Dufy, and L Bresson-Bepoldin
January 1993, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!